Table 2.

Adverse events assessed by CTCAE v3.0

Adverse eventsTotal (%)Grade 1 (%)Grade 2 (%)Grade 3 (%)Grade 4 (%)
Hemoglobin6 (66.7)5 (55.6)1 (11.1)00
Lymphopenia2 (22.2)2 (22.2)000
Injection site reaction8 (88.9)3 (33.3)5 (55.6)00

NOTE: Hemoglobin and lymphopenia were observed before the first vaccination. No other adverse events were seen throughout the period of peptide vaccination.